From the Food and Drug Administration.
Nightingale
S L
SL
D000418:Albumins / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects*; D001798:Blood Proteins / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D004348:Drug Labeling; D018073:Haemophilus Vaccines; D006801:Humans; D000069285:Infliximab; D010952:Plasma Substitutes / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D012712:Serum Globulins; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*; D014481:United States; D014486:United States Food and Drug Administration; D017778:Vaccines, Combined
D000418:Albumins; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D001798:Blood Proteins; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D010952:Plasma Substitutes; D018894:Reverse Transcriptase Inhibitors; D012709:Serum Albumin; D012712:Serum Globulins; D014409:Tumor Necrosis Factor-alpha; D017778:Vaccines, Combined; C008930:plasma protein fraction; D000069285:Infliximab; D000075462:Serum Albumin, Human